All > Primary Progressive Multiple Sclerosis > Multiple Sclerosis

Lutein for Multiple Sclerosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Multiple SclerosisLutein - DietarySupplement
Eligibility
18 - 64
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether lutein supplements can improve eyesight and cognition in people with multiple sclerosis.

Eligible Conditions
  • Multiple Sclerosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
home - exercise program
1
Active supplement
1
Early disclosure of genetic testing results

Study Objectives

5 Primary · 0 Secondary · Reporting Duration: 4 months (baseline vs. follow-up)

Month 4
Attentional Accuracy
Attentional Processing Speed
Attentional Reaction Time
Attentional Resource Allocation
Macular Pigment Optical Density

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
home - exercise program
1
Active supplement
2
Early disclosure of genetic testing results

Side Effects for

Control Plus Vitamin A
1%Death
This histogram enumerates side effects from a completed 2008 Phase 3 trial (NCT00346333) in the Control Plus Vitamin A ARM group. Side effects include: Death with 1%.

Trial Design

2 Treatment Groups

Lutein
1 of 2
Safflower Oil
1 of 2

Experimental Treatment

Non-Treatment Group

60 Total Participants · 2 Treatment Groups

Primary Treatment: Lutein · Has Placebo Group · N/A

Lutein
DietarySupplement
Experimental Group · 1 Intervention: Lutein · Intervention Types: DietarySupplement
Safflower Oil
DietarySupplement
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: DietarySupplement
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lutein
2016
Completed Phase 3
~550

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 4 months (baseline vs. follow-up)

Who is running the clinical trial?

National Institutes of Health Rehabilitation Research Resource to Enhance Clinical Trials (REACT)UNKNOWN
University of Illinois at Urbana-ChampaignLead Sponsor
169 Previous Clinical Trials
33,896 Total Patients Enrolled
14 Trials studying Multiple Sclerosis
603 Patients Enrolled for Multiple Sclerosis
Division of Nutritional Sciences, University of Illinois at Urbana-ChampaignUNKNOWN
1 Previous Clinical Trials
50 Total Patients Enrolled
Naiman Khan, PhDPrincipal Investigator - University of Illinois Urbana Champaign
University of Illinois at Urbana-Champaign
1 Previous Clinical Trials
288 Total Patients Enrolled

Eligibility Criteria

Age 18 - 64 · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have been diagnosed with relapsing-remitting MS (RRMS).
You have an EDSS score between 0-3.5.
You have macular pigment optical density of less than 0.35.
You have a score of 55 or less on the Symbol Digit Modalities Test (SDMT).

Who else is applying?

What state do they live in?
Illinois100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
University of Illinois at Urbana-Champaign100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top